Phase I study of low-dose hypomethylating agent azacitidine (5-AC) combined with the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced cancers
Year: 2006
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: F. Braiteh, A. Soriano, C. H. Luis, H. S. David, C. Ng, G. Garcia-Manero, R. Kurzrock
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2568189303